Picture loading failed.

Anti-FOLH1;CD3E therapeutic antibody (Pre-made Acapatamab biosimilar,Bispecific scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of non-small cell lung cancer (NSCLC).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-006-1mg 1mg Inquiry
GMP-Bios-ab-006-10mg 10mg Inquiry
GMP-Bios-ab-006-100mg 100mg Inquiry
GMP-Bios-ab-006-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-FOLH1;CD3E therapeutic antibody (Pre-made Acapatamab biosimilar,Bispecific scFv)
INN Name Acapatamab
TargetFOLH1;CD3E
FormatBispecific scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommended2021
CompaniesAmgen
Conditions Approvedna
Conditions ActiveCancers;Prostrate cancer;Metastatic cancer
Conditions Discontinuedna
Development TechBiTE Technology